Treatment of plaque-type psoriasis with the 308 nm excimer laser in combination with dithranol or calcipotriol. 2012

Christina Rogalski, and Sonja Grunewald, and Mario Schetschorke, and Marc Oliver Bodendorf, and Friederike Kauer, and Jan Christoph Simon, and Uwe Paasch
Department of Dermatology, Venereology and Allergology, University of Leipzig, Germany. christina.rogalski@medizin.uni-leipzig.de

OBJECTIVE The combination of excimer laser and topical treatment has not been studied in clinical trials. This within-patient comparison study evaluates the response rates of plaque-type psoriasis after treatment with topical only (dithranol or calcipotriol), laser only, and combination therapy with topical medication and laser. METHODS A total of 61 patients with psoriatic plaques located at symmetric body areas (PASI ≥ 6) were screened, 59 were enrolled, 54 completed treatment and 45 completed the 6 months follow-up. Treatments with the excimer laser were performed twice weekly until resolution or a maximum of 15 treatments. Each ointment was applied on one of the test lesions, which had to be at least 10 cm apart from each other. Efficacy was rated with a modified PASI score. RESULTS At the end of the treatment phase only one patient in both topical therapy regimens met the criteria of partial clearance (modified PASI ≤ 2). The combined therapies resulted in 23 cases of partial clearance in both treatment arms. Four areas treated with calcipotriol, respectively six areas treated with dithranol resulted in total clearance at the end of the treatment phase. The average reduction of modified PASI scores was higher in combination than in topical treatment alone (49.8% calcipotriol + excimer versus 22.9% calcipotriol, 49.7% dithranol + excimer versus 26.8% dithranol). After six months there was a total clearance of 30.5% dithranol + excimer. CONCLUSIONS Treatment of plaque-type psoriasis with laser in combination with topical treatment is a safe and effective therapy. The best long-term results can be obtained by the application of dithranol and excimer laser.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Christina Rogalski, and Sonja Grunewald, and Mario Schetschorke, and Marc Oliver Bodendorf, and Friederike Kauer, and Jan Christoph Simon, and Uwe Paasch
April 2011, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology,
Christina Rogalski, and Sonja Grunewald, and Mario Schetschorke, and Marc Oliver Bodendorf, and Friederike Kauer, and Jan Christoph Simon, and Uwe Paasch
June 2002, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],
Christina Rogalski, and Sonja Grunewald, and Mario Schetschorke, and Marc Oliver Bodendorf, and Friederike Kauer, and Jan Christoph Simon, and Uwe Paasch
April 2007, Journal of the European Academy of Dermatology and Venereology : JEADV,
Christina Rogalski, and Sonja Grunewald, and Mario Schetschorke, and Marc Oliver Bodendorf, and Friederike Kauer, and Jan Christoph Simon, and Uwe Paasch
May 2004, Archives of dermatology,
Christina Rogalski, and Sonja Grunewald, and Mario Schetschorke, and Marc Oliver Bodendorf, and Friederike Kauer, and Jan Christoph Simon, and Uwe Paasch
November 1997, Lancet (London, England),
Christina Rogalski, and Sonja Grunewald, and Mario Schetschorke, and Marc Oliver Bodendorf, and Friederike Kauer, and Jan Christoph Simon, and Uwe Paasch
January 2001, Archives of dermatology,
Christina Rogalski, and Sonja Grunewald, and Mario Schetschorke, and Marc Oliver Bodendorf, and Friederike Kauer, and Jan Christoph Simon, and Uwe Paasch
January 2004, Lasers in surgery and medicine,
Christina Rogalski, and Sonja Grunewald, and Mario Schetschorke, and Marc Oliver Bodendorf, and Friederike Kauer, and Jan Christoph Simon, and Uwe Paasch
May 2002, Journal of the American Academy of Dermatology,
Christina Rogalski, and Sonja Grunewald, and Mario Schetschorke, and Marc Oliver Bodendorf, and Friederike Kauer, and Jan Christoph Simon, and Uwe Paasch
November 2002, Journal of the American Academy of Dermatology,
Christina Rogalski, and Sonja Grunewald, and Mario Schetschorke, and Marc Oliver Bodendorf, and Friederike Kauer, and Jan Christoph Simon, and Uwe Paasch
August 2006, Photodermatology, photoimmunology & photomedicine,
Copied contents to your clipboard!